用安克洛酶进行去纤维蛋白治疗重度足部缺血：一项随机双盲研究。

Treatment of severe foot ischaemia by defibrination with ancrod: a randomized blind study.

作者信息

Tønnesen K H, Sager P, Gormsen J

出版信息

Scand J Clin Lab Invest. 1978 Sep;38(5):431-5. doi: 10.3109/00365517809108447.

Abstract

Forty-two patients, mean age 68 years, with severe leg ischaemia were randomly treated with placebo or by controlled defibrination with ancrod for 3 weeks. Plasma fibrinogen concentration was kept at about 20% of normal in the ancrod treated group. The two groups proved to be well matched regarding factors which could affect the degree of ischaemia. Objective measurements showed a significant rise in ankle and toe systolic blood pressure in the ancrod group lasting for 3 months. There was no rise in distal blood pressure in the control group. In the ancrod treated group the toe and ankle systolic pressures rose about 8 mmHg, but this was not accompanied by an improvement in the clinical course.

摘要

42名平均年龄为68岁的严重腿部缺血患者被随机分为两组，一组接受安慰剂治疗，另一组接受蝮蛇抗栓酶控制去纤维蛋白治疗，为期3周。在接受蝮蛇抗栓酶治疗的组中，血浆纤维蛋白原浓度维持在正常水平的约20%。两组在可能影响缺血程度的因素方面被证明具有良好的匹配性。客观测量结果显示，蝮蛇抗栓酶组的踝部和趾部收缩压显著升高，持续3个月。对照组的远端血压没有升高。在接受蝮蛇抗栓酶治疗的组中，趾部和踝部收缩压升高了约8 mmHg，但这并未伴随着临床病程的改善。